The prevalence and clinical characteristics of MS in northern Japan

Hideki Houzen1, Masaaki Niino, Seiji Kikuchi

  • 1Department of Neurology, Obihiro Kosei General Hospital, Obihiro, Japan.

Insights

This study found the highest multiple sclerosis (MS) prevalence in Japanese Orientals to date in Hokkaido, Japan. However, the optic-spinal form of MS was less common than previously reported in Japan.

Area of Science:

  • Neurology
  • Epidemiology
  • Neuroimmunology

Background:

  • Multiple sclerosis (MS) has a low prevalence in Japan, with a notable frequency of the optic-spinal form (OS-MS).
  • No intensive epidemiological studies on MS prevalence in Japan have been conducted for over 30 years.
  • Previous research indicated a relatively high OS-MS frequency in Japan compared to Western countries.

Purpose of the Study:

  • To conduct a province-wide prevalence study of MS in the Tokachi province of Hokkaido, Japan.
  • To determine the current prevalence rate of MS and compare clinical features with other Japanese and Western populations.
  • To investigate the frequency of the optic-spinal form of MS in this region.

Main Methods:

  • A prevalence study of MS was conducted in Tokachi province, Hokkaido, as of March 31, 2001.
  • Case ascertainment utilized data from 13 hospitals treating neurological diseases, including MS.
  • Patients were classified using Poser's criteria for clinically definite or laboratory-supported definite MS (LSDMS).

Main Results:

  • The prevalence rate of LSDMS in Tokachi province was 8.57 per 100,000 (31 cases out of 361,726 individuals).
  • The male/female ratio was 1:2.9, with a mean age at onset of 29.1 years.
  • Of the 31 MS patients, 5 (16%) were classified as OS-MS, a lower frequency than previously reported in Japan.

Conclusions:

  • The prevalence of MS in Hokkaido's Tokachi province is the highest reported among Orientals to date, though still lower than in Western countries.
  • Contrary to prior Japanese studies, the frequency of the optic-spinal form of MS was relatively low in Hokkaido.
  • This study highlights regional variations in MS epidemiology within Japan and provides updated prevalence data.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...